Fierce Biotech News & Reports
WEBThe Fierce 50 of 2024. Shining a spotlight on the people and companies who are driving meaningful change in healthcare, pharma and biotech. Ayla Ellison Sep 9, 2024 5:00am. Medtech News.
Biotech | Fierce Biotech
WEBFeb 12, 2024 · The companies will use Moderna’s mRNA-delivery nanoparticle platform to transport mRNA that codes for autoimmune targets directly into macrophages. Darren Incorvaia Sep 10, 2024 12:31pm. Connect.
MedTech | Fierce Biotech
WEBSep 10, 2024 · The tech giant plans to add sleep apnea detection to its Apple Watch and bring long-anticipated over-the-counter hearing aid tech to its AirPods. Conor Hale Sep 10, 2024 1:30pm. Connect. The Team ...
The top biotech hubs in 2022 - Fierce Biotech
WEBBy Annalee Armstrong Jul 5, 2022 12:00am. startups real estate venture capital (VC) small biotechs. Top cities for biotechs include Boston, San Francisco, San Diego and a little corner of North ...
Pharma - Fierce Biotech
WEB4 days ago · New findings for Zealand Pharma's weight loss candidate have emboldened the biotech to push the asset into a phase 2b trial. Gabrielle Masson Sep 10, 2024 10:45am. Connect.
Genentech to close cancer immunology research department
WEBBy Angus Liu Aug 16, 2024 11:08am. Roche Genentech immuno-oncology layoffs. Genentech will close its cancer immunology research department, and unit head and renowned cell biologist Ira Mellman ...
Regeneron to fill gaps in obesity, break ground in cell therapy
WEBFeb 2, 2024 · Regeneron wants to fill the gaps in care with a combo approach from its pipeline, adding trevogrumab or garetosmab to semaglutide (Wegovy) to improve the quality of weight loss that patients ...
8 months after a $213M fundraise, gene editor Tome makes cuts
WEBAug 22, 2024 · After $213M round, gene editing biotech Tome shrinks operations as investor sentiment worsens. After raising $213 million in 2023—one of the year’s largest private biotech rounds—Tome ...
Merck pays $700M for bispecific, spying autoimmune ... - Fierce …
WEBAug 9, 2024 · Merck & Co. is paying $700 million upfront to challenge Amgen in a blood cancer market. The deal will give Merck global rights to Curon Biopharmaceutical’s CD3xCD19 bispecific, positioning the ...
FierceMedTech's 2019 Fierce 15 - Fierce Biotech
WEBFierceMedTech's 2019 Fierce 15. By Conor Hale Mar 9, 2020 06:00am. Artificial Intelligence CRISPR diagnostic tests Digital health. These 15 companies embody the drive to make a significant ...
Skip to content